USFDA grants direct RMAT designation for the use of ExoFlo in Covid-19 related ARDS
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
Subscribe To Our Newsletter & Stay Updated